Serge Puksa
McMaster University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Serge Puksa.
The New England Journal of Medicine | 2013
Annette McWilliams; Martin C. Tammemagi; John R. Mayo; Heidi C. Roberts; Geoffrey Liu; Kam Soghrati; Kazuhiro Yasufuku; Simon Martel; Francis Laberge; Michel Gingras; Sukhinder Atkar-Khattra; Christine D. Berg; Kenneth G. Evans; Richard J. Finley; John Yee; John C. English; Paola Nasute; John R. Goffin; Serge Puksa; Lori Stewart; Scott Tsai; Michael R. Johnston; Daria Manos; Garth Nicholas; Glenwood D. Goss; Jean M. Seely; Kayvan Amjadi; Alain Tremblay; Paul Burrowes; Paul MacEachern
BACKGROUND Major issues in the implementation of screening for lung cancer by means of low-dose computed tomography (CT) are the definition of a positive result and the management of lung nodules detected on the scans. We conducted a population-based prospective study to determine factors predicting the probability that lung nodules detected on the first screening low-dose CT scans are malignant or will be found to be malignant on follow-up. METHODS We analyzed data from two cohorts of participants undergoing low-dose CT screening. The development data set included participants in the Pan-Canadian Early Detection of Lung Cancer Study (PanCan). The validation data set included participants involved in chemoprevention trials at the British Columbia Cancer Agency (BCCA), sponsored by the U.S. National Cancer Institute. The final outcomes of all nodules of any size that were detected on baseline low-dose CT scans were tracked. Parsimonious and fuller multivariable logistic-regression models were prepared to estimate the probability of lung cancer. RESULTS In the PanCan data set, 1871 persons had 7008 nodules, of which 102 were malignant, and in the BCCA data set, 1090 persons had 5021 nodules, of which 42 were malignant. Among persons with nodules, the rates of cancer in the two data sets were 5.5% and 3.7%, respectively. Predictors of cancer in the model included older age, female sex, family history of lung cancer, emphysema, larger nodule size, location of the nodule in the upper lobe, part-solid nodule type, lower nodule count, and spiculation. Our final parsimonious and full models showed excellent discrimination and calibration, with areas under the receiver-operating-characteristic curve of more than 0.90, even for nodules that were 10 mm or smaller in the validation set. CONCLUSIONS Predictive tools based on patient and nodule characteristics can be used to accurately estimate the probability that lung nodules detected on baseline screening low-dose CT scans are malignant. (Funded by the Terry Fox Research Institute and others; ClinicalTrials.gov number, NCT00751660.).
Journal of Thoracic Oncology | 2014
Sonya Cressman; Stephen Lam; Martin C. Tammemagi; William K. Evans; Natasha B. Leighl; Dean A. Regier; Corneliu Bolbocean; Frances A. Shepherd; Ming-Sound Tsao; Daria Manos; Geoffrey Liu; Sukhinder Atkar-Khattra; Ian Cromwell; Michael R. Johnston; John R. Mayo; Annette McWilliams; Christian Couture; John C. English; John R. Goffin; David M. Hwang; Serge Puksa; Heidi Roberts; Alain Tremblay; Paul MacEachern; Paul Burrowes; Rick Bhatia; Richard J. Finley; Glenwood D. Goss; Garth Nicholas; Jean M. Seely
Background: It is estimated that millions of North Americans would qualify for lung cancer screening and that billions of dollars of national health expenditures would be required to support population-based computed tomography lung cancer screening programs. The decision to implement such programs should be informed by data on resource utilization and costs. Methods: Resource utilization data were collected prospectively from 2059 participants in the Pan-Canadian Early Detection of Lung Cancer Study using low-dose computed tomography (LDCT). Participants who had 2% or greater lung cancer risk over 3 years using a risk prediction tool were recruited from seven major cities across Canada. A cost analysis was conducted from the Canadian public payer’s perspective for resources that were used for the screening and treatment of lung cancer in the initial years of the study. Results: The average per-person cost for screening individuals with LDCT was
Journal of Thoracic Oncology | 2017
Sonya Cressman; Stuart Peacock; Martin C. Tammemagi; William K. Evans; N. Leighl; John R. Goffin; Alain Tremblay; Geoffrey Liu; Daria Manos; Paul MacEachern; Rick Bhatia; Serge Puksa; Garth Nicholas; Annette McWilliams; John R. Mayo; John Yee; John C. English; Reka Pataky; Emily McPherson; Sukhinder Atkar-Khattra; Michael R. Johnston; Heidi Schmidt; Frances A. Shepherd; Kam Soghrati; Kayvan Amjadi; Paul Burrowes; Christian Couture; Harmanjatinder S. Sekhon; Kazuhiro Yasufuku; Glenwood D. Goss
453 (95% confidence interval [CI],
Brachytherapy | 2015
Nhu-Tram A. Nguyen; Emilia Timotin; Robert Hunter; Crystal Hann; Serge Puksa; Ranjan Sur
400–
Radiotherapy and Oncology | 2016
Elysia Donovan; Emilia Timotin; Tom Farrell; Bernard Donde; Serge Puksa; Ranjan Sur
505) for the initial 18-months of screening following a baseline scan. The screening costs were highly dependent on the detected lung nodule size, presence of cancer, screening intervention, and the screening center. The mean per-person cost of treating lung cancer with curative surgery was
Chest | 2015
Alain Tremblay; Niloofar Taghizadeh; Annette McWilliams; Paul MacEachern; David R. Stather; Kam Soghrati; Serge Puksa; John R. Goffin; Kazuhiro Yasufuku; Kayvan Amjadi; Garth Nicholas; Simon Martel; Francis Laberge; Michael R. Johnston; Frances A. Shepherd; Diana N. Ionescu; Stefan J. Urbanski; David M. Hwang; Jean-Claude Cutz; Harmanjatinder S. Sekhon; Christian Couture; Zhaolin Xu; Tom G. Sutedja; Sukhinder Atkar-Khattra; Martin C. Tammemagi; Ming-Sound Tsao; Stephen Lam
33,344 (95% CI,
Brachytherapy | 2015
Mira Goldberg; Emilia Timotin; Tom Farrell; Serge Puksa; Bernard Donde; Ranjan Sur
31,553–
Brachytherapy | 2017
Elysia Donovan; E. Timotin; Tom Farrell; Bernard Donde; Serge Puksa; Ranjan Sur
34,935) over 2 years. This was lower than the cost of treating advanced-stage lung cancer with chemotherapy, radiotherapy, or supportive care alone, (
Journal of Thoracic Oncology | 2018
J. Turner; Gregory R. Pond; Alain Tremblay; Michael R. Johnston; Glenwood D. Goss; Garth Nicholas; Simon Martel; Rick Bhatia; Geoffrey Liu; Heidi Schmidt; Martin C. Tammemagi; Serge Puksa; Sukhinder Atkar-Khattra; M. Tsao; S. Lam; John R. Goffin
47,792; 95% CI,
Journal of Thoracic Oncology | 2017
John R. Goffin; Gregory R. Pond; Alain Tremblay; Michael R. Johnston; Glenwood D. Goss; Garth Nicholas; Simon Martel; Rick Bhatia; Geoffrey Liu; Heidi Roberts; Martin C. Tammemagi; Sukhinder Atkar-Khattra; M. Tsao; S. Lam; Serge Puksa
43,254–